Gudjonsson JE

No ORCID on file · 2 papers in corpus
2020
Drugs in R&D ·doi:10.1007/s40268-020-00311-6

The prevalence of cutaneous adverse events attributable to newly approved anti-cancer drugs has been well reviewed in the dermatologic literature. In contrast, over 75% of US Food and Drug Administration approvals in the past 5 years have b…

2019
The Journal of investigative dermatology ·doi:10.1016/j.jid.2018.09.018

Immune-mediated diseases affect more than 20% of the population, and many autoimmune diseases affect the skin. Drug repurposing (or repositioning) is a cost-effective approach for finding drugs that can be used to treat diseases for which t…